Maddi Hebebrand, MC, Associate Editor

Patients undergoing plastic surgery have the highest prevalence of BDD at 24%.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Genetic proxies for PCSK9 inhibition were consistently associated with reduced vitiligo risk across 2 biobanks.

Tapinarof offers sustained relief for atopic dermatitis, enabling treatment-free periods and long-term disease control—even in young children.

Phototherapy, commonly used for vitiligo, might help reduce cardiovascular risk through anti-inflammatory effects.

In a large study, nearly half of SIND patients also had other BFRBs like skin picking or hair pulling.

Untreated or undertreated AD can lead to poor sleep, infections, and stunted development.

Experts explore how rosacea research is evolving, with new treatments, gaps in care, and a push for more inclusive, targeted approaches.

Explore the top headlines of the week including insights on infection risks, drug updates, and more.

This week, we feature top articles from our sister publications on FDA approvals, innovative tech updates, and more.

Satisfaction levels remained high at 12 weeks post-treatment among those who received acupuncture.

While approved for vitiligo and atopic dermatitis, ruxolitinib cream may help treat other inflammatory skin diseases.

Microneedles successfully penetrated simulated skin barriers, suggesting their effectiveness in reaching sebaceous glands.

Bill Damsky, MD, PhD, pioneers molecular diagnostics to close the gap between research and clinical care in inflammatory skin disease.

Physicians can customize treatment depth and intensity with Avava’s system, improving results for various skin concerns.

Treatment decisions are increasingly guided by patient values, preferences, and quality-of-life considerations.

Compared to untreated patients, dupilumab-treated women showed no increased risk for spontaneous abortion, gestational diabetes, or hypertensive disorders.

The guide prepares students to critically engage with AI tools and understand their real-world implications.

Current JAK inhibitors are approved only for those 12 and older, leaving younger patients without access.

Explore the top headlines of the week including insights on pandemic risks, weight loss medications, and more.

This week, we feature top articles from our sister publications on the future of health care, FDA approvals, and more.

The study found dupilumab-treated patients had the highest probability of remaining infection-free over 52 weeks.

Studies show that exposure to meaningful artwork can lower blood pressure and enhance mental clarity in patients.

Unlike biologics, nonbiologic systemic therapies showed a neutral or slightly increased cardiovascular risk, raising concerns about their long-term safety.

The study stated early recognition and aggressive treatment of childhood-onset MMP are essential to prevent permanent scarring.

Researchers call for standardized methods to assess and report ADWEs in deprescribing trials to ensure reliable data and clinical confidence.

Bio-naïve patients and those without comorbidities had the highest treatment success rates with guselkumab.

Microbiome engineering offers strategies to modulate the skin microbiome, including non-targeted approaches like probiotics and targeted approaches like phage therapy.

The significance of patient education and setting realistic expectations for the often-slow process of repigmentation in vitiligo treatment was a key focus of the discussion.

The integration of pharmacotherapy in obesity treatment provides a structured approach to weight loss for patients who struggle with traditional methods.